Conopeptides from cone snail venom that target nicotinic acetylcholine receptors show promise as dual-action treatments for chemotherapy-induced neuropathy by simultaneously blocking pain signals and reducing neuroinflammation.
Zero FDA-approved CIPN preventivesDespite chemotherapy-induced neuropathy affecting up to 70% of patients receiving certain drugs, no preventive treatment exists — making conopeptides a high-priority research area.
What the researchers found
The review highlights α-conotoxins RgIA4 and GeXIVA[1,2] as lead candidates for CIPN treatment. These peptides specifically target α9-containing nicotinic acetylcholine receptors (nAChRs), which play critical roles in both neuronal excitability and inflammatory responses in peripheral and central sensory pathways.
These conopeptides demonstrate dual therapeutic mechanisms: direct blockade of pain signaling through ion channel modulation, and reduction of neuroinflammation through neuroimmune pathway modulation. In animal models of CIPN, these peptides have shown disease-modifying potential rather than just symptom relief. Recent peptide engineering advances have improved their cross-species compatibility, receptor selectivity, and serum stability for potential clinical development.
Why it matters
CIPN affects up to 70% of cancer patients receiving certain chemotherapy drugs and often persists long after treatment ends. There are no FDA-approved preventive therapies. Current pain management (gabapentin, duloxetine) offers only modest relief and doesn't address the underlying nerve damage. Conopeptides that both block pain and reduce the neuroinflammation driving nerve damage could be the first disease-modifying treatments for this condition.
How the study worked
This is a narrative review synthesizing published research on conopeptide pharmacology, nicotinic acetylcholine receptor biology in CIPN, animal model studies, and recent advances in peptide engineering for improved drug-like properties.
What this study cannot tell us
As a review, this synthesizes existing preclinical research rather than presenting new data. Most evidence comes from animal models of CIPN, and the translation to human nerve pain is uncertain. Conopeptides face significant pharmacokinetic challenges including limited oral bioavailability, short half-lives, and potential immunogenicity. The specific clinical development timelines and regulatory paths for these peptides are not discussed.
How to read the evidence
This is a narrative review of preclinical research. The evidence for conopeptides in CIPN comes primarily from animal models. No human clinical trial data for CIPN-specific applications are included. The evidence is promising but early-stage.
When this study was published
Published in 2026, this is the most current review of conopeptides for CIPN, incorporating the latest advances in peptide engineering and receptor pharmacology.
The bigger picture
Cone snail venom has already yielded one FDA-approved pain drug — ziconotide (Prialt) — which blocks calcium channels for severe chronic pain. Conopeptides targeting nicotinic receptors represent the next frontier. The CIPN application is particularly compelling because it addresses a growing unmet need as cancer survival rates improve and more patients live with treatment side effects. The peptide engineering advances described in this review (improving stability, selectivity, and cross-species activity) are bringing these venom-derived molecules closer to clinical viability.
Questions still open
- Can conopeptides like RgIA4 prevent CIPN when given alongside chemotherapy, or only treat it after it develops?
- How close are these conopeptides to entering human clinical trials for CIPN?
- Could conopeptide-based treatments for CIPN be delivered locally to affected nerves to avoid systemic side effects?
Common questions
What are conopeptides and how are they related to pain treatment?
Why is chemotherapy-induced neuropathy so hard to treat?
Read the original research
Conopeptides as Modulators of Pain and Inflammation in Chemotherapy-Induced Peripheral Neuropathy by Targeting α7 and α9 Nicotinic Acetylcholine Receptors.
Neurotoxicity research, 44(1), 3
Citation
Mosayyebi, Bashir; Faradonbeh, Davood Rabiei; Hosseindoost, Saereh; Arsanjani, Amirhossein Akbarpour; Negahdari, Babak; Majedi, Hossein; Malekshahi, Ziba Veisi. (2026). Conopeptides as Modulators of Pain and Inflammation in Chemotherapy-Induced Peripheral Neuropathy by Targeting α7 and α9 Nicotinic Acetylcholine Receptors.. Neurotoxicity research, 44(1), 3. https://doi.org/10.1007/s12640-025-00778-8